{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-056503","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-12-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.287512+00:00","generated_at":"2026-06-07T16:50:17.189043+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"GNI Japan revises FY2023 profit forecast up ¥6.97B on conversion of Gyre preferred stock","bullets":["GNI Japan recognized ¥8,873M other income from converting Gyre Series X Preferred into 8,767,333 common shares.","Revised FY2023 operating profit forecast ¥15,744M (up 116% from ¥7,280M); profit attributable to owners ¥8,971M (up 347%).","Revised EPS forecast ¥180.42 vs previous ¥42.20; prior year ¥8.19.","Conversion based on $0.51/share closing price of CBIO on Oct 30, 2023; shares to be issued Jan 22, 2024.","Forecast excludes mark-to-market of Gyre common stock; further discussions ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-056503","json":"https://secwatch.observer/filing/0001140361-23-056503.json","markdown":"https://secwatch.observer/filing/0001140361-23-056503.md","text":"https://secwatch.observer/filing/0001140361-23-056503.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123056503/0001140361-23-056503-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123056503/ef20016120_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T16:50:17.189043+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}